Novel coronavirus (2019-nCoV) updates from FDA

February 5, 2020

Novel coronavirus (2019-nCoV)

FDA is working with U.S. Government partners, including the U.S. Centers for Disease Control and Prevention (CDC), and international partners to closely monitor an outbreak caused by a novel (new) coronavirus first identified in Wuhan City, Hubei Province, China. On January 27, 2020, FDA announced critical actions to advance development of novel coronavirus medical countermeasures. As with any emerging public health threat, FDA is collaborating with interagency partners, product developers, international partners, and global regulators to expedite the development and availability of medical products needed to diagnose, treat, mitigate and prevent such outbreaks.

Learn more:  2019-nCoV updates from FDA

Related links: Important Information for Blood Establishments Regarding the Novel Coronavirus Outbreak, from the FDA Center for Biologics Evaluation and Research (CBER) (February 4, 2020) For more updates from FDA, follow @SteveFDA, @US_FDA, @FDA_Global, and @FDA_MCMi on Twitter 2019 Novel Coronavirus (CDC) Secretary Azar Declares Public Health Emergency for United States for 2019 Novel Coronavirus (HHS) (January 31, 2020) Also see EUA updates and Information for industry below